Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.
Department of Medicine, Saint Vincent Hospital, Worcester; Department of Nephrology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Cancer Res Ther. 2022 Jul-Sep;18(4):1180-1182. doi: 10.4103/jcrt.JCRT_1107_19.
Essential thrombocytosis (ET) is usually an indolent disease but can uncommonly evolve into acute myeloid leukemia (AML) with a grim prognosis of 2-7 months. Studies report a lower incidence of leukemic transformation when compared to fibrotic transformation. The risk of transformation depends on the age, duration of disease, and tumor biology. Hydroxyurea, a cytoreductive agent, is generally associated with minimal adverse reactions; however, there are conflicting data on its effect on leukogenecity. We describe a rare case of a 79-year-old female developing disseminated intravascular coagulation due to the transformation of ET to both AML and myelofibrosis while being treated with hydroxyurea for 8 years.
原发性血小板增多症（ET）通常为惰性疾病，但也可罕见转化为急性髓系白血病（AML），预后极差，中位生存期为 2-7 个月。与纤维化转化相比，研究报告称其白血病转化的发生率较低。转化风险取决于年龄、疾病持续时间和肿瘤生物学。减细胞药物羟基脲通常与最小的不良反应相关；然而，其对白血病发生的影响存在矛盾的数据。我们描述了一例罕见病例，一名 79 岁女性在接受羟基脲治疗 8 年后，由于 ET 同时转化为 AML 和骨髓纤维化而发生弥漫性血管内凝血（DIC）。
